Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.

Bioscience reports - 30 Apr 2020

Lv Jia, Zhu Yongze, Ji Alin, Zhang Qi, Liao Guodong

Abstract excerpt

BACKGROUND: Bladder cancer is the ninth most-common cancer worldwide and it is associated with high morbidity and mortality. Tumor mutational burden (TMB) is an emerging biomarker in cancer characterized by microsatellite instability. TMB has been described as a powerful predictor of tumor behavior and response to immunotherapy. METHODS: A total of 443 bladder cancer samples obtained from The Cancer Genome Atlas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Datasets as Topic

Share to Killer Cells, Natural

Share to Mast Cells

Share to Microsatellite Instability

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32239176
DOI: 10.1042/BSR20194337
PMCID: PMC7178217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.PMID 32239176Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.Semantic proximity Read ↗

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.Semantic proximity Read ↗

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancerSemantic proximity Read ↗

Analysis of genome-wide mutation profile and establishment of risk signature for prognosis of bladder cancerSemantic proximity Read ↗

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.Semantic proximity Read ↗

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.Semantic proximity Read ↗

Multi-Omics Analysis Identifies the Heterogeneity and Prognosis in Bladder CancerSemantic proximity Read ↗

Identification of RB1 Gene as a Immune-Related Prognostic Signature Based on Tumor Mutation Burdens in Bladder CancerSemantic proximity Read ↗

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics studySemantic proximity Read ↗

The Cancer Genome Atlas Project in Bladder Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.